Celcuity Inc. Unveils Presentation on Advancements in Treating Cancers Involving PI3K/AKT/mTOR Pathway

Reuters
28 May
<a href="https://laohu8.com/S/CELC">Celcuity Inc</a>. Unveils Presentation on Advancements in Treating Cancers Involving PI3K/AKT/mTOR Pathway

Celcuity Inc. has unveiled a corporate presentation highlighting its developments in targeting cancers involving the PI3K/AKT/mTOR $(PAM)$ pathway, a significant area in oncology. The company focuses on leveraging gedatolisib, a differentiated PAM inhibitor with a potent and well-tolerated mechanism of action, showing promising data in both first-line and second-line patients with HR+/HER2- advanced breast cancer. The presentation also outlines plans for Phase 3 studies and discusses the potential for developing treatments for prostate cancer due to parallels with breast cancer. Celcuity is strategically positioned to advance multiple indications in breast and prostate cancer, supported by substantial cash reserves. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Celcuity Inc. published the original content used to generate this news brief on May 28, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10